Compare
UroGen Pharma Ltd. vs Zevra Therapeutics, Inc. vs Zymeworks Inc. vs Gyre Therapeutics, Inc.
| Latest fiscal year | UroGen Pharma Ltd. URGN | Zevra Therapeutics, Inc. ZVRA | Zymeworks Inc. ZYME | Gyre Therapeutics, Inc. GYRE |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $109.79M | $106.47M | $105.97M | $116.59M |
| Revenue growth (YoY) | +21.4% | +350.9% | +38.9% | +10.2% |
| Gross margin | 88.7% | n/a | n/a | n/a |
| Operating margin | -113.7% | -59.1% | -87.3% | 9.9% |
| Net margin | -139.8% | 78.2% | -76.6% | 8.5% |
| Net income | -$153.49M | $83.23M | -$81.13M | $9.88M |
| EPS (Diluted) | n/a | $1.35 | -$1.08 | $0.02 |
| Operating cash flow | -$162.44M | -$1.60M | -$33.01M | $1.01M |
| Free cash flow | -$162.73M | -$2.43M | -$34.53M | -$180.0K |
| Cash & equivalents | $110.75M | $62.41M | $41.16M | $37.07M |
| Total assets | $200.46M | $284.73M | $346.53M | $166.13M |
| Total liabilities | $305.93M | $130.07M | $78.03M | $23.85M |
| Shareholders' equity | -$105.47M | $154.66M | $268.50M | $106.03M |
| Return on year-end equity | n/a | 53.8% | -30.2% | 9.3% |
| Shares outstanding | 48.35M | 56.85M | 74.64M | 91.31M |
Revenue, most recent five fiscal years
| Fiscal year | UroGen Pharma Ltd. | Zevra Therapeutics, Inc. | Zymeworks Inc. | Gyre Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $109.79M Ended 2025-12-31 | $106.47M Ended 2025-12-31 | $105.97M Ended 2025-12-31 | $116.59M Ended 2025-12-31 |
| 1 year earlier | $90.40M Ended 2024-12-31 | $23.61M Ended 2024-12-31 | $76.30M Ended 2024-12-31 | $105.76M Ended 2024-12-31 |
| 2 years earlier | $82.71M Ended 2023-12-31 | $27.46M Ended 2023-12-31 | $76.01M Ended 2023-12-31 | $113.45M Ended 2023-12-31 |
| 3 years earlier | $64.36M Ended 2022-12-31 | $10.16M Ended 2022-12-31 | $412.48M Ended 2022-12-31 | $102.29M Ended 2022-12-31 |
| 4 years earlier | $48.04M Ended 2021-12-31 | $28.65M Ended 2021-12-31 | $26.68M Ended 2021-12-31 | $7.34M Ended 2021-12-31 |